Pattern of malignant disorders in individuals with Down's syndrome

The Lancet Oncology
H Hasle

Abstract

The pattern of occurrence of malignant disorders in people with Down's syndrome (DS) is unique and may serve as a model in the search for leukaemogenic genes and tumour suppressor genes on chromosome 21, since the risk of leukaemia is higher in individuals with DS than in non-DS individuals. Acute lymphoblastic leukaemia in DS shares many of the clinical characteristics of the same malignancy in other patients, and with current intensive therapy the long-term survival is similar. Myelodysplastic syndrome and acute myeloid leukaemia have unique clinical characteristics in these patients and are best described as a single disorder, termed myeloid leukaemia of DS. When these patients are treated intensively, they show better survival rates than patients without DS. This may be related to increased expression of genes on chromosome 21 contributing to increased chemosensitivity. Chronic myeloid leukaemia and chronic lymphocytic leukaemia occur less often than expected. With the exception of an increased risk of retinoblastoma, germ-cell tumours, and perhaps lymphomas, the risk of developing solid tumours is lower in both children and adults. Breast cancer is almost absent, and the risk of a second malignant disease after treatment f...Continue Reading

References

Oct 1, 1990·Human Genetics·L IseliusN Morton
May 1, 1995·Medical and Pediatric Oncology·J M OlsonN E Breslow
Mar 1, 1994·Leukemia Research·A ZipurskyJ Doyle
Sep 15, 1996·Experientia·R De La TorreJ Sáez
Jun 18, 1999·Archives of Disease in Childhood·J L CrazeJ M Chessells
Oct 16, 1999·British Journal of Haematology·H HasleK R Schultz
Dec 22, 1999·Journal of Pediatric Hematology/oncology·K ChoongA Zipursky
Sep 1, 1957·A.M.A. Journal of Diseases of Children·W KRIVIT, R A GOOD

❮ Previous
Next ❯

Citations

Oct 26, 2012·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Luzhou XingBenjamin Tycko
Jun 16, 2009·Human Genetics·David Patterson
Apr 14, 2006·Biogerontology·Federico V PallardóGiovanni Pagano
Feb 6, 2004·Blood Cells, Molecules & Diseases·George B Segel, Marshall A Lichtman
Nov 10, 2012·Leukemia·C BohnstedtUNKNOWN Nordic Society of Pediatric Hematology and Oncology (NOPHO)
Jun 11, 2010·Nature·Louise E ReynoldsKairbaan M Hodivala-Dilke
Jan 5, 2005·Nature Reviews. Cancer·Johann K Hitzler, Alvin Zipursky
Jan 11, 2005·Nature Reviews. Genetics·David Patterson, Alberto C S Costa
Mar 30, 2010·Médecine sciences : M/S·Catherine Turleau, Michel Vekemans
Mar 20, 2009·Human Molecular Genetics·Frances K WisemanElizabeth M C Fisher
Mar 20, 2009·Human Molecular Genetics·Ithamar GanmoreShai Izraeli
Aug 17, 2006·Journal of Pediatric Hematology/oncology·Erik ForestierUNKNOWN Nordic Society of Paediatric Haematology and Oncology NOPHO
Jan 7, 2009·Journal of Pediatric Hematology/oncology·Catherine BohnstedtKjeld Schmiegelow
Feb 11, 2012·Journal of Pediatric Hematology/oncology·Mitsuaki IshidaHidetoshi Okabe
Mar 3, 2010·Genes & Development·Jan-Henning KlusmannDirk Reinhardt
Feb 23, 2012·The Journal of Clinical Investigation·Sébastien MalingeJohn D Crispino
Feb 23, 2012·The Journal of Clinical Investigation·Yehudit Birger, Shai Izraeli
Mar 6, 2009·World Journal of Surgical Oncology·Fadi S FarhatWalid Daya
Apr 6, 2006·PLoS Genetics·Randall J Roper, Roger H Reeves
May 3, 2011·PloS One·Valerio CostaAlfredo Ciccodicola
Jan 19, 2013·Cardiology in the Young·Morten OlsenJørgen Videbæk
Sep 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Mireille J AlemanRamaswamy Narayanan
Sep 13, 2013·Molecular Cytogenetics·Erica Aires GilGeraldo Barroso Cavalcanti Júnior
May 20, 2009·Epidemiology·Tone BjørgeAnnekatrin Lukanova
Sep 5, 2002·Medical and Pediatric Oncology·Charles Stiller
Nov 25, 2011·European Journal of Pediatrics·Annelyse Bruwier, Christophe F Chantrain
Jan 1, 2010·Retinal Cases & Brief Reports·Basil K WilliamsTimothy G Murray
Jun 17, 2004·British Journal of Haematology·Shai Izraeli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.